In this study, 347 @entity1 with @entity43 without @entity41 after primary laparotomy, were assigned randomly to receive either intraperitoneal instillation of radioactive @entity3151 (32P) or six courses of @entity900 (50 mg/m2). @entity1 randomized to receive 32P with extensive intraperitoneal adhesions were treated with whole-abdomen irradiation instead of 32P (n = 28). The median follow-up was 62 months. Crude and disease-free survival were similar in all groups. Late bowel complications occurred more often in @entity1 treated with 32P compared with the @entity900 group. The estimated 5-year crude survival rate was as high as 95% in @entity1 with borderline or well-differentiated @entity5 in Stage I. It is suggested that these @entity1 can be treated adequately by operation alone. @entity1 with moderately or poorly differentiated @entity5 in Stage I disease had a 5-year crude survival rate of 75%. In these @entity1 , the relapse risk was high enough to warrant postoperative treatment. The efficacy of adjuvant treatment in this subgroup of @entity1 can only be established in a prospective randomized study comparing postoperative adjuvant treatment with a no-treatment arm. Because of the high number of late bowel complications after 32P treatment, it was recommended that @entity900 be used as standard adjuvant treatment for subsequent controlled studies.

Randomized trial comparing @entity900 with radioactive @entity3151 or whole-abdomen irradiation as adjuvant treatment of XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity43 :: ('MESH:D010051', 'Disease') :: ['epithelial ovarian cancer'] @entity41 :: ('MESH:D018365', 'Disease') :: ['residual tumor'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers', 'tumors'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity3151 :: ('MESH:D010758', 'Chemical') :: ['phosphorus']
@entity43 :: (MESH:D010051,Disease) :: ['ovarian cancer']
